Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 9TB-500 (Thymosin Beta-4 Fragment) literatureNatureTop journal2012

In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes.

Not reported in abstract.

Read at NatureAdd to compare

Where it sits

this study against the rest of the tb-500 (thymosin beta-4 fragment) corpus
4
Preclinical · this one
4
Observational
0
Open-label
0
Randomised
1
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2012

Abstract

The authors’ words, as Nature supplied them

The reprogramming of adult cells into pluripotent cells or directly into alternative adult cell types holds great promise for regenerative medicine. We reported previously that cardiac fibroblasts,which represent 50%of the cells in the mammalian heart, can be directly reprogrammed to adult cardiomyocyte-like cells in vitro by the addition of Gata4, Mef2c and Tbx5 (GMT). Here we use genetic lineage tracing to show that resident non-myocytes in the murine heart can be reprogrammed into cardiomyocyte-like cells in vivo by local delivery of GMT after coronary ligation. Induced cardiomyocytes became binucleate, assembled sarcomeres and had cardiomyocyte-like gene expression. Analysis of single cells revealed ventricular cardiomyocyte-like action potentials, beating upon electrical stimulation, and evidence of electrical coupling. In vivo delivery of GMT decreased infarct size and modestly attenuated cardiac dysfunction up to 3 months after coronary ligation. Delivery of the pro-angiogenic and fibroblast-activating peptide, thymosin b4, along with GMT, resulted in further improvements in scar area and cardiac function. These findings demonstrate that cardiac fibroblasts can be reprogrammed into cardiomyocyte-like cells in their native environment for potential regenerative purposes.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the TB-500 (Thymosin Beta-4 Fragment) corpus

DDe novo cardiomyocytes from within the activated adult heart after injury.Nature · 2011CJMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy.mAbs · 2026 · Not reported in abstract.AnimalBOTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.Cell cycle (Georgetown, Tex.) · 2026 · Not reported in abstract.HumanBConstruction and validation of a prediction model for graft failure in pediatric liver transplant recipients based on the APRI-ALBI score: a retrospective study of 289 cases.Annals of medicine · 2026 · n=289 · AUC of 0.706 for the nomogram predicting graft failure.HumanCThymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Reviewbiorxiv-preprint · 2026 · Not reported in abstract.reviewDSemantic Scholar search for TB-500 (Thymosin Beta-4)SemanticScholar · 2026